Binx is currently a one trick pony mate. They have the IO reader which we have distribution rights for. Which means, we obtain revenue from the sales of both the reader and the cartridges. If LDX are in fact manufacturing the cartridges, then we obtain revenue from the manufacturing of these cartridges as well as the sale of each device.Barrie indicated that the test Lumos was looking at releasing was already in market. It likely means that they have developed a more portable version of what Binx or another party has. You might find that the reader Binx has is not very suitable for point of care and given LDX has a variety of tests which can be used on their platform, and have distribution rights to Binx's tests, an agreement may come about where Binx removes their IO platform and run the tests on the Lumos system?
Something you may have missed also:
Its not only Binx we have the rights for.
Lumos is using the distribution rights for all these products as a sales tool to include their own products via the distribution channels.
So they make money from the distribution of others products as well as their own sales.
(20min delay)